According to the study, ‘Dry Powder Inhaler Devices - Medical Devices Pipeline
Assessment, 2018’, Some companies operating in this industry
along with their products are Acorda Therapeutics Inc, CVT-427 Drug Delivery
Device; Aespira Ltd., resQhaler; Bayer AG, Ciprofloxacin Dry Powder Inhaler;
Bespak Europe Ltd, DEV610 DPI; Boehringer Ingelheim GmbH, Next Generation
Respimat Inhaler; Circassia Pharmaceuticals Plc, Tiotropium bromide DPI;
GlaxoSmithKline Plc, Gemini Multi-Dose Combination Inhaler; MannKind Corp,
Dreamboat; MannKind Corp, Treprostinil Technosphere; Respira Therapeutics Inc,
RT234 AOS DPI; Sandoz International GmbH, Solis Multi-Dose Dry Powder Inhaler;
Sun Pharma Advanced Research Company Ltd, SPARC DPI; Verona Pharma Plc, RPL554
- Dry Powder Inhaler.
Dry powdered inhalers (DPIs) are widely
accepted inhaler devices primarily used in Europe where it is often used to
treat chronic obstructive pulmonary and asthma. The acceptance of these devices
in the United States can be primarily correlated to introduction of 2 well
known drugs. These are Advair Diskus and Serevent Diskus. The prime advantage
of DPIs is that it offers convenience to consumers especially for combination
therapies. The design, development and formation of any powder drug delivery
system is a very complex task. The key is to match device geometry with the
choice of formulation. Good quality aerosol in terms of aerosol’s aerodynamic
particle size is one of the most important factors in pulmonary delivery from
DPI.
There are primarily 2 types of dry
powdered inhalers currently. One in which drug is packaged in a gelatin blister
or foil capsule and the other in which there is a reservoir of drug from which
doses are metered out. These devices are becoming relatively popular as they do
not require chlorofluorocarbon propellant to spread the drug which makes these
devices eco friendly. The efficiency of these devices to in dispersion of the
aerosol is also a key factor that leads to their huge success. Other benefits
include reduced need for patient coordination, less potential for formulation
problems. Environmental factors especially humidity and temperature also affect
the functionality of these devices.
Recent developments in this industry
include focus on delivery system that disaggregates the powder as this
effectively minimizes formulation development work. The current devices that
are in use are too bulky and heave that limits mobility. Companies are trying
to develop devices that are much smaller in design and simultaneously ensuring
that the efficiency does not go down. A multi dose reservoir has been developed
that can be used for the delivery of formoterol. One of the most recent developments
is the breezhaler device. This is a single dose DPI which functions on aerolizer
technology with many design changes which ensure device handling. Capsules
containing acting beta-adrenergic bronchodilator indacaterol maleate and the
long-acting muscarinic antagonist glycopyrronium are used by this device to
deliver the drug. This device has been structured in a manner to lower the
internal airflow resistance.
In the last decade, the world has
witnessed increasing usage of dry powdered inhaler devices primarily because of
their efficiency and eco friendly nature. The future of this industry shall
focus more on consistence, reliability, efficiency and mobility. All these
factors shall ensure greater penetration of DPIs especially in the developing
markets. The growth potential for these devices is definitely high which could
be tapped if the manufacturers are able to keep up with improvements in pharmaceutical
industries also.
For More Information, Refer to the Link below:-
Related Report:
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
Sales@kenresearch.com
+91-9015378249
Ken Research
Ankur Gupta, Head Marketing & Communications
Sales@kenresearch.com
+91-9015378249
